Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
Healthcare Asia Magazine on MSN
Lucence, DXD Hub, and NCCS launch $6m UNITED 2.0 cancer test
The team will adopt a dual WES-WTS approach for more detailed tumour profiling. Lucence, Diagnostics Development Hub hosted ...
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...
Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. The Caris Assure® platform is a ...
Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
RNA library preparation can make or break whole transcriptome sequencing data acquisition. Speed, sensitivity, and scalability are key workflow considerations, but researchers often face bottlenecks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results